Horizon Therapeutics Plc
NASDAQ:HZNP 12:25:27 AM EDT
Regulatory, Other Pre-Announcement
Horizon Therapeutics PLC Expects Short-Term Disruption In Tepezza Supply
Published: 12/17/2020 11:30 GMT
Horizon Therapeutics Plc (HZNP) - Horizon Therapeutics Plc - Expects Short-term Disruption in Tepezza Supply.
Horizon Therapeutics Plc - Anticipates That Drug Supply Shortage Will Begin at End of December and Could Last Through Q1 of 2021.
Horizon Therapeutics Plc - Expects to Submit Data in January From First Increased Scale Manufacturing Lot to FDA for Review.
Horizon Therapeutics Plc - Does Not Anticipate Short-term Supply Disruption Will Impact Its Full-year 2020 Financial Guidance.
Horizon Therapeutics - Expects Disruption in Tepezza Supply Due to Government-mandated Covid-19 Vaccine Production Orders.
Horizon Therapeutics Plc - Expects to Have More Than $2 Billion of Cash and Cash Equivalents at December 31, 2020.
Horizon Therapeutics - Also Plans to Delay Start of Its Planned Tepezza Clinical Trial in Chronic Ted Until Q2 2021.
Horizon Therapeutics - Also Plans to Delay Start of Its Tepezza Exploratory Trial in Diffuse Cutaneous Systemic Sclerosis Until Q2 2021.
Horizon Therapeutics - Assuming Chronic Ted Trial is Initiated in Q2 2021, Co Would Continue to Anticipate Data in Q1 2022.
Horizon Therapeutics Plc - Anticipates That Drug Supply Shortage Will Begin at End of December and Could Last Through Q1 of 2021.
Horizon Therapeutics Plc - Expects to Submit Data in January From First Increased Scale Manufacturing Lot to FDA for Review.
Horizon Therapeutics Plc - Does Not Anticipate Short-term Supply Disruption Will Impact Its Full-year 2020 Financial Guidance.
Horizon Therapeutics - Expects Disruption in Tepezza Supply Due to Government-mandated Covid-19 Vaccine Production Orders.
Horizon Therapeutics Plc - Expects to Have More Than $2 Billion of Cash and Cash Equivalents at December 31, 2020.
Horizon Therapeutics - Also Plans to Delay Start of Its Planned Tepezza Clinical Trial in Chronic Ted Until Q2 2021.
Horizon Therapeutics - Also Plans to Delay Start of Its Tepezza Exploratory Trial in Diffuse Cutaneous Systemic Sclerosis Until Q2 2021.
Horizon Therapeutics - Assuming Chronic Ted Trial is Initiated in Q2 2021, Co Would Continue to Anticipate Data in Q1 2022.